Inventor · disambiguated record
Kazuhiko Shigeno
Also filed as: SHIGENO KAZUHIKO
9 granted patents·2 pending applications·144 citations·filing 1995–2023
88Inventor score
Files withTAIHO PHARMACEUTICAL CO LTD5STANFORD RES INST INT3URADE YOSHIHIRO2TAIHO PHARMACEUTICALS CO LTD1
Top patents by PatentIndex Score
11 records- 0182US8865714B2Piperazine compound capable of inhibiting prostaglandin D synthaseURADE YOSHIHIRO·Filed 2010·Granted Oct 21, 2014·10 cites·6 claims
- 0282US5763432ASteriod inhibitors of estrone sulfatase and associated pharmaceutical compositions and methods of useSTANFORD RES INST INT·Filed 1997·Granted Jun 9, 1998·38 cites·13 claims
- 0381US6046186AEstrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of useSTANFORD RES INST INT·Filed 1997·Granted Apr 4, 2000·55 cites·65 claims
- 0477US9062035B2Piperazine compound capable of inhibiting prostaglandin D synthaseTAIHO PHARMACEUTICAL CO LTD·Filed 2014·Granted Jun 23, 2015·4 cites·2 claims
- 0567US8765750B2Piperazine compound having a PGDS inhibitory effectURADE YOSHIHIRO·Filed 2011·Granted Jul 1, 2014·2 cites·7 claims
- 0659US5728841AProcess for preparing 1-amino-1,2,3-triazoleTAIHO PHARMACEUTICAL CO LTD·Filed 1995·Granted Mar 17, 1998·9 cites·5 claims
- 0758US6110967AEpoxysuccinamide derivative or salt thereofTAIHO PHARMACEUTICALS CO LTD·Filed 1998·Granted Aug 29, 2000·18 cites·23 claims
- 0854US2025178998A1Crystal form of cyclohexenone compoundTAIHO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0951US5861388ASteroid inhibitors of estrone sulfatase and associated pharmaceutical compositions and methods of useSTANFORD RES INST INT·Filed 1997·Granted Jan 19, 1999·8 cites·22 claims
- 1045US2023295068A1Novel cycloalkenone compound or salt thereofTAIHO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 1144US6818764B2Process for preparing substance GM-95TAIHO PHARMACEUTICAL CO LTD·Filed 2001·Granted Nov 16, 2004·0 cites·6 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →